FDA has approved FoundationOne Liquid CDx for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
